REG - N4 Pharma PLC - siRNA update

N4 PharmaAnnouncement

18/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230418:nRSR4804Wa&default-theme=true

RNS Number : 4804W  N4 Pharma PLC  18 April 2023

18 April 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

siRNA update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to provide an update on its ongoing siRNA research work.

 

The Company has completed the single loading of both the EGFR and BCL-2 siRNA
nucleotides onto Nuvec and has produced good monodisperse formulations at all
doses to be investigated. The single loaded EGFR siRNA has shown strong
silencing of the EGFR gene with a good dose response curve established which
has allowed the Company to identify the dose it can take into the single
loaded EGFR in vivo study.

The next step for EGFR is to measure cell apoptosis to show a relevant in
vitro clinical effect.

Supply of siRNA is only available from a few sources and supply issues means
the Company is still establishing the BCL-2 assay to be used for the in vitro
testing. An initial effect has been seen but to complete the dose response
curve more material is needed to fully establish the assay and determine the
doses to move into the single loaded in vivo work and double loaded
experiments.

The Company has also established the growth curve of the xenograft tumour
model to be used, so once the BCL-2 in vitro work is complete, the Company
will be ready to start the in vivo studies, as long as supply of the siRNA is
not further interrupted.

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We are very pleased with the EGFR results which show excellent knockdown of
the siRNA along with a very clear dose response curve and believe this shows
how well suited Nuvec® is for working with siRNA."

 

Enquiries:

 N4 Pharma Plc                                          Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                         Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                  Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 IFC Advisory Limited                                   Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

Glossary

siRNA: silencing RNA / short interfering RNA

Nucleotides: organic molecules composed of a nitrogenous base, a pentose sugar
and a phosphate.

EGFR: epidermal growth factor receptor, is found on the surface of some normal
cells and is involved in cell growth. It may also be found at high levels on
some types of cancer cells, which causes these cells to grow and divide.

Bcl-2: (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the
founding member of the Bcl-2 family of regulator proteins that regulate cell
death.

Monodisperse: (of a colloid) containing particles of uniform size.

 

Xenograft tumour model: in vivo model where human tumour cells are grown to
form a tumour.

 

Cell apoptosis: the process of programmed cell death.

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive upfront payments, milestone
payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESBUGDSSDBDGXR